Biomaterial Database

Metastatic prostate cancer to lung with normal prostate specific antigen levels. 2004

Nathan Lawrentschuk, and David R Webb, and Catherine A Mitchell

Department of Urology, Austin and Repatriation Medical Centre, Heidelberg, Victoria, 3084, Australia.

UI	MeSH Term	Description	Entries
D008175	Lung Neoplasms	Tumors or cancer of the LUNG.	Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297	Male		Males
D011471	Prostatic Neoplasms	Tumors or cancer of the PROSTATE.	Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368	Aged	A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available.	Elderly
D017430	Prostate-Specific Antigen	A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.	Kallikrein hK3,gamma-Seminoprotein,hK3 Kallikrein,Prostate Specific Antigen,Semenogelase,Seminin,Kallikrein, hK3,gamma Seminoprotein
D018931	Antineoplastic Agents, Hormonal	Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)	Hormonal Antineoplastic Agents,Antineoplastic Drugs, Hormonal,Antineoplastic Hormonal Agents,Antineoplastic Hormonal Drugs,Antineoplastics, Hormonal,Hormonal Agents, Antineoplastic,Hormonal Antineoplastic Drugs,Hormonal Antineoplastics,Agents, Antineoplastic Hormonal,Drugs, Antineoplastic Hormonal,Hormonal Drugs, Antineoplastic

Related Publications

Nathan Lawrentschuk, and David R Webb, and Catherine A Mitchell

Metastatic prostate cancer with a normal prostate-specific antigen level.

October 2005, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico,

Nathan Lawrentschuk, and David R Webb, and Catherine A Mitchell

Metastatic prostate cancer with normal level of serum prostate-specific antigen.

January 2003, International urology and nephrology,

Nathan Lawrentschuk, and David R Webb, and Catherine A Mitchell

[Metastatic prostate cancer associated with low levels of prostate-specific antigen].

January 2012, Revista peruana de medicina experimental y salud publica,

Nathan Lawrentschuk, and David R Webb, and Catherine A Mitchell

Clinical and US findings in prostate cancer: patients with normal prostate-specific antigen levels.

November 1993, Radiology,

Nathan Lawrentschuk, and David R Webb, and Catherine A Mitchell

Elevated serum prostate-specific antigen levels in a woman with metastatic breast cancer.

September 2000, The New England journal of medicine,